Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  antiangiogenesis therapy
Results 1-25 of 479 for your search:
Start Over
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Phase: Phase IV
Type: Treatment
Age: Not specifiec
Trial IDs: CRAD001C2X01B, NCI-2013-01151, NCT01789281
Sorafenib Tosylate in Treating Patients with Advanced Liver Cancer and Hepatitis C Infection
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-213, NCI-2013-01103, NCT01849588
Lenalidomide or Observation in Treating Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E3A06, NCI-2011-02057, CDR0000682012, ECOG-E3A06, NCT01169337
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: TG4010.14/TIME, NCI-2013-00825, 8559, TG4010.14/TIME, 8559, NCT01383148
Sorafenib Long Term Extension Program (STEP)
Phase: Phase III
Type: Treatment
Age: 16 and over
Trial IDs: 12311, NCI-2012-01207, 2007-002604-17, NCT00625378
Lenalidomide with or without Epoetin Alfa in Treating Patients with Myelodysplastic Syndrome and Anemia
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: E2905, NCI-2009-01173, CDR0000634119, ECOG-E2905, NCT00843882
Everolimus in Treating Patients with Kidney Cancer Who Have Undergone Surgery
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0931, NCI-2011-02028, CDR0000668388, SWOG-S0931, NCT01120249
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1200.131, NCI-2012-02044, 2011-000392-14, NCT01345669
A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MO22097, NCI-2012-00367, NCT01351415
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AB06002, NCI-2013-00616, NCT01470131
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TS-103, NCI-2012-01029, NCT01556490
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AGS-003-007, NCI-2013-00717, 2012-000871-17, NCT01582672
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AP311736, NCI-2014-01024, NCT01599754
Sorafenib Tosylate with or without Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 1112, NCI-2012-02057, NCT01730937
Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CC-4047-MM-007, NCI-2013-00024, NCT01734928
Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 15982, NCI-2013-01156, 2012-003649-14, NCT01774344
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 2012-005, NCI-2014-02181, 2012-005283-97, NCT01818752
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: C16014, NCI-2013-01188, 163325, 2013-000326-54, U1111-1158-2646, NCT01850524
Start Over